Value Creation Through Constructive Activism
Our Investment Focus
We focus on investing in and providing value-added assistance through constructive activism to what we believe are substantially undervalued small, publicly traded companies that have potential for significant turnarounds.
Our goal is that the result of our constructive activism leads to a reversal in direction for the share prices of these investee companies…
i.e., a 180-degree turn.
Our investment portfolio includes publicly traded companies that we believe were undervalued at the time of our initial investment and have the potential to build value in large and growing markets.
Adesto (NASDAQ:IOTS) offers the world’s lowest power memory solutions unleashing innovation for a new class of connected applications and previously unimagined devices.
Mersana (NASDAQ:MRSN) develops immunoconjugate therapies leveraging its Fleximer platform to create precisely targeted and highly tailored drugs.
Synacor (NASDAQ:SYNC) is the trusted technology development, multiplatform services and revenue partner for video, internet and communications providers, device manufacturers, and enterprises.
TheStreet, Inc. (NASDAQ:TST) provides timely unbiased news, powerful data and strong analysis to help consumers and businesses make informed investment decisions and discover new business opportunities.
While our current investment focus is in opportunities in publicly traded companies, we are committed to shepherding our existing investments in privately held portfolio companies to maximize returns on those investments.
ABSMaterials develops high performance, transformative absorbent technology solutions for a wide range of industrial applications.
Accelerator is a biotechnology investment and management company with offices in New York City and Seattle.
AgBiome is a biotechnology company using new knowledge of the plant-associated microbiome to create innovative products for agriculture.
D-Wave Systems is a quantum computing company whose computers help solve some of the world’s most complex challenges.
EchoPixel is building interactive, 3D medical visualization software.
HALE.life is a precision health and medicine company reimagining the primary care experience.
Lodo Therapeutics identifies and produces bioactive natural products directly from the microbial DNA sequence information contained in soil.
Nanosys develops quantum dot technology for displays.
NGX Bio provides accurate, fast, and affordable genetic sequencing services.
ORIG3N is focused on the understanding and treatment of rare genetically inherited diseases.
Petra Pharma is a drug development company focused on novel enzyme targets that play a central role in a variety of important cellular processes.
Phylagen is focused on harnessing the vast, unseen world of microbes to improve business performance and make our lives better.
ProSep (Produced Water Absorbents) provides the oil and gas industry with innovative oil, gas, and produced water separation solutions.
TARA is developing predictive cardiac tissue models that enable faster, safer, and more reliable development of new medicines.
180 Degree Capital is excited to be able to provide the opportunity for shareholders and other interested parties who are accredited investors to co-invest alongside 180 in its most exciting companies. These co-investments will be facilitated through individual, special purpose funds set up and managed by 180.
Our Management Team
Upcoming & Past Events
- 180 Degree Capital Corp. to Report First Quarter 2019 Financial Results on Wednesday, May 1, 2019 and to Host a Conference Call on Thursday, May 2, 2019
- 180 Degree Capital Corp.’s CEO, Kevin M. Rendino, Appointed to the Board of Its Portfolio Company, Synacor, Inc.
- 180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.64 as of December 31, 2018; a Decrease of 6% From Prior Quarter and an Increase of 1.5% From December 31, 2017
7 N. Willow Street, Suite 4B
Montclair, NJ 07042
NOTE: Please do not send us business plans for privately held companies as we no longer make new investments in privately held companies.
Investor Relations Contact